The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine.

Gunaydin S, Imai Y, Takanashi Y, Seo K, Hagino I, Chang D, Shinoka T

Cardiovascular surgery (London, England)1 Apr 2002Cited by 23 (Europe PMC)

PMID11888743DOI10.1177/096721090201000209PepBankPUB-11888743

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rabbits with pulmonary hypertension after cardiopulmonary bypass, VIP 10(-5) M increased mean arterial pressure more than isoproterenol.
In plain wordsIn rabbits, VIP at the higher dose raised mean blood pressure more than isoproterenol.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseMean arterial pressure versus isoproterenol
Study
rabbitn: not reported in source
Monocrotaline-induced pulmonary hypertension after cardiopulmonary bypass
Comparator
Isoproterenol
Outcome group
Blood pressure · Cardiovascular
Studied dose
10(-5) M · perfused after cardiopulmonary bypass · 60 minAs given in this study (rabbit).
Source sentences
Summary
VIP 10(-5) M increased MAP and decreased PAP significantly with respect to isoproteronol and VIP 10(-6) M (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied in vivo effects in monocrotaline induced pulmonary hypertensive rabbits immediately after cardiopulmonary bypass (CPB) and tested them versus calcium channel and beta-blockers.
Summary · context
The study consisted of six groups (N=30; five rabbits/group): (1) Control with no pretreatment, monocrotaline injected groups: (solutions were perfused following termination of CPB for 60 min); (2) Control for pulmonary hypertension (PHT); (3) isoproteronol; (4) VIP 10(-6) M; (5) VIP 10(-5) M; (6) nitroglycerine.
Report a problemFND-1188874301
02AnimalAnimal study (in vivo)Efficacy outcome
In rabbits with pulmonary hypertension after cardiopulmonary bypass, VIP 10(-5) M increased mean arterial pressure more than VIP 10(-6) M.
In plain wordsIn rabbits, VIP at the higher dose raised mean blood pressure more than VIP at the lower dose.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseMean arterial pressure versus lower VIP dose
Study
rabbitn: not reported in source
Monocrotaline-induced pulmonary hypertension after cardiopulmonary bypass
Comparator
VIP 10(-6) M
Outcome group
Blood pressure · Cardiovascular
Studied dose
10(-5) M · perfused after cardiopulmonary bypass · 60 minAs given in this study (rabbit).
Source sentences
Summary
VIP 10(-5) M increased MAP and decreased PAP significantly with respect to isoproteronol and VIP 10(-6) M (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied in vivo effects in monocrotaline induced pulmonary hypertensive rabbits immediately after cardiopulmonary bypass (CPB) and tested them versus calcium channel and beta-blockers.
Summary · context
The study consisted of six groups (N=30; five rabbits/group): (1) Control with no pretreatment, monocrotaline injected groups: (solutions were perfused following termination of CPB for 60 min); (2) Control for pulmonary hypertension (PHT); (3) isoproteronol; (4) VIP 10(-6) M; (5) VIP 10(-5) M; (6) nitroglycerine.
Report a problemFND-1188874302
03AnimalAnimal study (in vivo)Efficacy outcome
In rabbits with pulmonary hypertension after cardiopulmonary bypass, VIP 10(-5) M decreased pulmonary artery pressure more than isoproterenol.
In plain wordsIn rabbits, VIP at the higher dose lowered lung artery pressure more than isoproterenol.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePulmonary artery pressure versus isoproterenol
Study
rabbitn: not reported in source
Monocrotaline-induced pulmonary hypertension after cardiopulmonary bypass
Comparator
Isoproterenol
Outcome group
Vascular function · Cardiovascular
Studied dose
10(-5) M · perfused after cardiopulmonary bypass · 60 minAs given in this study (rabbit).
Source sentences
Summary
VIP 10(-5) M increased MAP and decreased PAP significantly with respect to isoproteronol and VIP 10(-6) M (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied in vivo effects in monocrotaline induced pulmonary hypertensive rabbits immediately after cardiopulmonary bypass (CPB) and tested them versus calcium channel and beta-blockers.
Summary · context
The study consisted of six groups (N=30; five rabbits/group): (1) Control with no pretreatment, monocrotaline injected groups: (solutions were perfused following termination of CPB for 60 min); (2) Control for pulmonary hypertension (PHT); (3) isoproteronol; (4) VIP 10(-6) M; (5) VIP 10(-5) M; (6) nitroglycerine.
Report a problemFND-1188874303
04AnimalAnimal study (in vivo)Efficacy outcome
In rabbits with pulmonary hypertension after cardiopulmonary bypass, VIP 10(-5) M decreased pulmonary artery pressure more than VIP 10(-6) M.
In plain wordsIn rabbits, VIP at the higher dose lowered lung artery pressure more than VIP at the lower dose.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePulmonary artery pressure versus lower VIP dose
Study
rabbitn: not reported in source
Monocrotaline-induced pulmonary hypertension after cardiopulmonary bypass
Comparator
VIP 10(-6) M
Outcome group
Vascular function · Cardiovascular
Studied dose
10(-5) M · perfused after cardiopulmonary bypass · 60 minAs given in this study (rabbit).
Source sentences
Summary
VIP 10(-5) M increased MAP and decreased PAP significantly with respect to isoproteronol and VIP 10(-6) M (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied in vivo effects in monocrotaline induced pulmonary hypertensive rabbits immediately after cardiopulmonary bypass (CPB) and tested them versus calcium channel and beta-blockers.
Summary · context
The study consisted of six groups (N=30; five rabbits/group): (1) Control with no pretreatment, monocrotaline injected groups: (solutions were perfused following termination of CPB for 60 min); (2) Control for pulmonary hypertension (PHT); (3) isoproteronol; (4) VIP 10(-6) M; (5) VIP 10(-5) M; (6) nitroglycerine.
Report a problemFND-1188874304
05AnimalAnimal study (in vivo)Efficacy outcome
In rabbits with pulmonary hypertension after cardiopulmonary bypass, VIP 10(-5) M decreased pulmonary resistance at the 15th minute after bypass.
In plain wordsIn rabbits, VIP at the higher dose lowered lung vessel resistance early after bypass.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePulmonary resistance at 15 min after bypass
Study
rabbitn: not reported in source
Monocrotaline-induced pulmonary hypertension after cardiopulmonary bypass
Outcome group
Vascular function · Cardiovascular
Studied dose
10(-5) M · perfused after cardiopulmonary bypass · 60 minAs given in this study (rabbit).
Source sentences
Summary
VIP 10(-5) M also decreased Rp significantly in the early post CPB 15th minute (P<0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
We studied in vivo effects in monocrotaline induced pulmonary hypertensive rabbits immediately after cardiopulmonary bypass (CPB) and tested them versus calcium channel and beta-blockers.
Summary · context
The study consisted of six groups (N=30; five rabbits/group): (1) Control with no pretreatment, monocrotaline injected groups: (solutions were perfused following termination of CPB for 60 min); (2) Control for pulmonary hypertension (PHT); (3) isoproteronol; (4) VIP 10(-6) M; (5) VIP 10(-5) M; (6) nitroglycerine.
Report a problemFND-1188874305
06AnimalAnimal study (in vivo)Efficacy outcome
In rabbits with pulmonary hypertension after cardiopulmonary bypass, VIP 10(-5) M showed no superiority to other agents in pulmonary resistance after the 15th minute.
In plain wordsIn rabbits, VIP at the higher dose was not better than the other agents at lowering lung vessel resistance later on.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changePulmonary resistance after the 15th minute
Study
rabbitn: not reported in source
Monocrotaline-induced pulmonary hypertension after cardiopulmonary bypass
Comparator
Other agents
Outcome group
Vascular function · Cardiovascular
Studied dose
10(-5) M · perfused after cardiopulmonary bypass · 60 minAs given in this study (rabbit).
Source sentences
Summary
but did not show any superiority to other agents in the following minutes.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied in vivo effects in monocrotaline induced pulmonary hypertensive rabbits immediately after cardiopulmonary bypass (CPB) and tested them versus calcium channel and beta-blockers.
Summary · context
The study consisted of six groups (N=30; five rabbits/group): (1) Control with no pretreatment, monocrotaline injected groups: (solutions were perfused following termination of CPB for 60 min); (2) Control for pulmonary hypertension (PHT); (3) isoproteronol; (4) VIP 10(-6) M; (5) VIP 10(-5) M; (6) nitroglycerine.
Report a problemFND-1188874306

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

07AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism
In rabbits after cardiopulmonary bypass, verapamil inhibited the effects of VIP 10(-5) M.
In plain wordsIn rabbits, verapamil blocked the effects of VIP, which points to calcium channels.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseVerapamil inhibition of VIP 10(-5) M effects
Study
rabbitn: not reported in source
Monocrotaline-induced pulmonary hypertension after cardiopulmonary bypass
Comparator
VIP 10(-5) M without verapamil
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
Verapamil inhibited VIP 10(-5) M effects but propranol did not.
3 context sentences(design, population, supporting numbers)
Summary · context
The VIP 10(-5) M group was subjected to an additional 1.7 x 10(-6) M propranol and 2 mM verapamil infusions for a further 15 min.
Summary · context
We studied in vivo effects in monocrotaline induced pulmonary hypertensive rabbits immediately after cardiopulmonary bypass (CPB) and tested them versus calcium channel and beta-blockers.
Summary · context
The study consisted of six groups (N=30; five rabbits/group): (1) Control with no pretreatment, monocrotaline injected groups: (solutions were perfused following termination of CPB for 60 min); (2) Control for pulmonary hypertension (PHT); (3) isoproteronol; (4) VIP 10(-6) M; (5) VIP 10(-5) M; (6) nitroglycerine.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1188874307
08AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism
In rabbits after cardiopulmonary bypass, propranolol did not inhibit the effects of VIP 10(-5) M.
In plain wordsIn rabbits, propranolol did not block the effects of VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changePropranolol and VIP 10(-5) M effects
Study
rabbitn: not reported in source
Monocrotaline-induced pulmonary hypertension after cardiopulmonary bypass
Comparator
VIP 10(-5) M without propranolol
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
but propranol did not.
3 context sentences(design, population, supporting numbers)
Summary · context
The VIP 10(-5) M group was subjected to an additional 1.7 x 10(-6) M propranol and 2 mM verapamil infusions for a further 15 min.
Summary · context
We studied in vivo effects in monocrotaline induced pulmonary hypertensive rabbits immediately after cardiopulmonary bypass (CPB) and tested them versus calcium channel and beta-blockers.
Summary · context
The study consisted of six groups (N=30; five rabbits/group): (1) Control with no pretreatment, monocrotaline injected groups: (solutions were perfused following termination of CPB for 60 min); (2) Control for pulmonary hypertension (PHT); (3) isoproteronol; (4) VIP 10(-6) M; (5) VIP 10(-5) M; (6) nitroglycerine.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1188874308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.